MedPath

MYLAN-AZELASTINE/FLUTICASONE

MYLAN-AZELASTINE/FLUTICASONE

Approved
DIN Number

02530341

Drug Class

Human

Market Date

Aug 16, 2023

Company
HC

Mylan Pharmaceuticals ULC

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02530341
AIG Number0256150002
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
R01AD58 FLUTICASONE, COMBINATIONS
Product Specifications
Dosage FormSpray, Metered Dose
Route of AdministrationNasal
AHFS Classification04:08.00
Health Canada Classification

ACTIVE INGREDIENTS (2)

AZELASTINE HYDROCHLORIDEActive
Strength: 137 MCG / ACT
Monograph: AZELASTINE HYDROCHLORIDE
FLUTICASONE PROPIONATEActive
Strength: 50 MCG / ACT
Monograph: FLUTICASONE PROPIONATE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.